Autologous stem cell transplant (SCT) improves survival in multiple myeloma (MM) and remains the standard of care for eligible patients. Nearly a third of patients with newly diagnosed MM fail initial therapy aimed at reducing tumor burden preceding SCT (primary refractory). It is unclear if an initial response is important for successful SCT. We evaluated our experience with SCT in 50 patients with primary refractory MM and compared it to 101 patients with chemosensitive disease receiving SCT. The study cohort had a median age of 56 years (range 29-72) consisting of 87 males (58%). A total of 46 patients (92%) in the refractory group and 100 (99%) in the chemosensitive group had a response to transplant (50% or greater reduction in the M-protein). In all, 10 refractory patients (20%) and 35 (35%) in the chemosensitive group achieved a CR (P ¼ 0.06). The 1-year estimated progresion-free survival from the time of transplant for the refractory group was 70% compared to 83% for the chemosensitive group (P ¼ 0.65). The lack of response to initial induction therapy does not appear to preclude a good response to SCT. We recommend that patients with primary refractory MM be offered early SCT.
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Multiple myeloma, a clonal plasma cell-proliferative disorder, accounts for nearly 10% of all hematological neoplasms and 1% of all malignancies. 1 There will be an estimated 14 600 new cases of multiple myeloma in this country in 2003 alone and 10 800 will die of the disease. 2 The median age of onset is in the mid-60s and the median survival with conventional chemotherapy is 3 years. 1, 3 Introduction of different combination chemotherapies has not resulted in improved survival compared to melphalan and prednisone, which was introduced in the early 70s. 4, 5 Dose intensification using high-dose chemotherapy with autologous stem cell rescue has been used increasingly in an attempt to improve response rates and survival. In prospective randomized trials, high-dose therapy and autologous stem cell transplantation (SCT) have resulted in improved progressionfree and overall survival compared to conventional therapy. 6, 7 The impact on overall survival has been confirmed in population-based studies as well. 8 Some studies suggest an additional advantage with double or tandem autologous stem cell transplants in selected groups of patients. 9, 10 High-dose therapy and autologous transplantation have become widely accepted and is the preferred therapy for patients with myeloma who are able to undergo the procedure. Typically, patients with newly diagnosed multiple myeloma receive initial therapy with a nonalkylating agent regimen to obtain a response prior to stem cell harvest. Alkylating agent use prior to stem cell collection adversely affects collection and should be avoided. Different approaches to induction therapy include the administration of three to four cycles of induction therapy prior to harvest or administration of multiple cycles of chemotherapy to maximal response. The role of induction therapy in these patients slated for high-dose therapy remains unclear. Patients who fail to achieve a response to the initial therapy (ie, primary refractory) represent a distinct population. Studies in other B-cell malignancies such as non-Hodgkin's lymphoma have demonstrated poor results with autologous transplantation for patients who do not have chemosensitive disease at the time of transplantation. 11, 12 It is not clear if this is true for multiple myeloma. Previous studies have suggested that refractory patients do better with transplantation compared to other aggressive forms of chemotherapy. 13, 14 In this study we have evaluated our center's experience with autologous transplantation for patients with primary refractory disease.
Patients and methods

Patients
In all, 151 patients with multiple myeloma, who underwent stem cell collection and transplantation between April 1991 and February 2002, form the subjects for this study. Patients were grouped into two categories: those demonstrating a response to initial induction therapy (defined as an achievement of 50% or greater reduction in monoclonal protein level) and transplanted immediately after three to four cycles of therapy (chemosensitive group) vs those who were primary refractory (defined as failure to achieve a 50% or greater reduction in monoclonal protein level with initial standard-dose chemotherapy regimen). Patients who were transplanted at relapse after a response to initial therapy (late transplants) were excluded. Data pertaining to the transplant patients are captured prospectively into a database that is continuously updated. Complete follow-up was available for all patients. All patients had provided written informed consent for use of their medical records. Approval of the Mayo Foundation Institutional Review Board was obtained in accordance with federal regulations and the Declaration of Helsinki.
The majority of patients (84 patients, 55%) initially received infusional chemotherapy with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy for four cycles. The dexamethasone was administered as originally described at 40 mg/day on days 1-4, 9-12, and 17-20 for all four treatment cycles. 15 In all, 28 patients (19%) had induction therapy with dexamethasone alone and 24 patients (16%) had dexamethasone in combination with thalidomide given for four cycles. The dexamethasone was given at 40 mg/day on days 1-4, 9-12, and 17-20. In the combination therapy, thalidomide was given at 200 mg/day. The remaining 15 patients had one or more of thalidomide as single agent, melphalan with prednisone or the combination of vincristine, BCNU, melphalan, cyclophosphamide, and prednisone (VBMCP) as their initial therapy. A total of 15 patients had exposure to melphalan prior to stem cell harvest, with cumulative exposure ranging from 48 to 630 mg.
In all but one patient, stem cells were collected after initial administration of cyclophosphamide 1.5 g/m 2 per day for 2 consecutive days. This was followed by sargramostim (GM-CSF) at 5 mg/kg, starting on day 3, and continuing until collection was complete. Apheresis was performed once the total white blood cell count exceeded 0.5 Â 10 9 /l. The remaining patient had stem cells collected using filgrastim administered subcutaneously (5 mg/kg) daily until the completion of peripheral blood stem cell collection with apheresis beginning on the fifth day after starting G-CSF. Prior to 1997, the target for the apheresis procedure was 5 Progression-free survival (PFS) was measured as time from transplantation to relapse, disease progression, or death. Overall survival from transplantation or diagnosis was defined as the time from transplantation or from the date of initial diagnosis of myeloma to the date of death or last follow-up, respectively.
Bone marrow plasma cell labeling index (PCLI), cytogenetics, b2 microglobulin and other laboratory variables were assessed pre-transplantation. Labeling index, which is a measure of the cell kinetics, was determined using a slide-based immunofluorescence method on bone marrow samples, as previously described, 17 and is classified as high when 41%.
Factors of interest were compared between patient groups (ie chemosensitive vs primary refractory patients). These factors included: age at diagnosis, age at transplant, gender, serum M protein level at transplant, C-reactive protein (CRP), PCLI, percentage of bone marrow plasma cells (BMPC), b 2 microglobulin, serum immunoglobulin heavy chain, light chain, incidence of abnormal cytogenetics, circulating plasma cells at harvest, induction regimen, conditioning regimen, whether or not a complete response was achieved, Durie-Salmon stage, presence of bone disease, time to engraftment for ANC (4500) and platelets (450 000), incidence of post-transplant bacteremia, and TRM. The w 2 and Fisher exact tests were used to compare differences among the patient groups for nominal variables and the nonparametric Wilcoxon rank sum test was used for continuous variables. In addition, progression-free and overall survival from the time of transplant was evaluated using Kaplan-Meier analyses and Cox proportional hazards models. Differences in these timed end points between the above factors as well as patient group were tested for statistical significance using the two-tailed log-rank test. 18 Given the high level of censoring for overall survival and the length of available follow-up, only differences in the 1-year survival rates from either time of diagnosis or transplant were calculated between the patient groups (chemosensitive vs primary refractory). Multivariate analysis was performed using the Cox proportional hazards model. 19 Any factors that had a P-value o0.05 in the univariate analyses were carried forward for exploration in the multivariate model. All P-values represented were two-sided.
Results
The study population consisted of 151 patients, of which 87 were male (58%), and the median age was 56 years (range 29-72). There were no significant differences in the demographic characteristics between the two groups. Two-thirds of patients (n ¼ 101) had obtained an objective response to initial therapy prior to transplant. The remaining 50 patients (33%) had refractory disease. The median time to transplant from diagnosis of myeloma was similar for the two groups (P ¼ 0.80; chemosensitive: 6.5 months vs primary refractory: 6.2 months). The median duration from the initial therapy to the transplant was similar between the chemosensitive (median 6 months; range 3-13) and the refractory (median 5.4 months; range 4-20) groups; P ¼ 0.4. The median follow-up from diagnosis for patients alive at last follow-up was 39 months (range 16-127 months) and from transplant was 32 months (range 9-119 months). There was no difference in the type of initial chemotherapy regimens between the two groups.
Baseline clinical and laboratory features
The baseline characteristics at transplant, which were different between the two patient groups, are detailed in Table 1 . In all, 45 patients (30%) were Durie-Salmon stage II and 106 patients (70%) were stage III, and the distribution was similar between the two groups. Only four patients had a creatinine over 2.0 mg/dl at transplant. Markers of tumor burden and/or disease activity including b2 M, bone marrow plasmacytosis, labeling index, serum M-protein level, and circulating plasma cells were higher in the refractory group at the time of transplant, reflecting lack of response to initial therapy. A total of 30 patients (20%) had abnormal cytogenetics: the chemosensitive group had significantly fewer patients with abnormal cytogenetics (13%) compared to the refractory group (34%) (P ¼ 0.001). This also included six patients in the refractory group and three in the chemosensitive group with deletion 13.
Conditioning, toxicity and engraftment
More patients in the chemosensitive group received melphalan only conditioning compared to the refractory group (77 vs 60%; P ¼ 0.02). The median post-transplant hospital stay was slightly higher for the refractory group (14 days vs 13 days; P ¼ 0.04). The median time to WBC and platelet engraftment was similar in the two groups. An ANC of 0.5 Â 10 9 /l was not achieved by 30 days in nine patients (6%) and an unsupported platelet count of 50 Â 10 9 /l was not reached by 60 days in 11 (7%) patients. The most common post-transplant toxicities encountered included nausea, mucositis, diarrhea, and neutropenic fever, and were similar for the two groups. Less common toxicities included hepatic veno-occlusive disease, ARDS, and CMV pneumonitis.
Response
The overall response rate for the entire group was 97%, with a slightly higher response rate for the chemosensitive group (99%) compared to the primary refractory group (92%); P ¼ 0.02. In all, 45 patients (30%) have achieved a complete response (chemosensitive: 35% vs primary refractory: 20%; P ¼ 0.06). Among the responders, 48 patients (33%) have subsequently progressed including 13 patients who had achieved a CR.
Survival
At the time of analysis, 111 patients (74%) were alive. A total of 32 patients died either of relapse, progressive disease or due to complications arising from salvage therapy for relapsed disease. Four patients died of transplant-related mortality, defined as death in the first year post-transplant without disease progression (one and three in the two groups, respectively). One patient died of late infection while still in remission, and three of other causes unrelated to disease relapse. The 1-year survival rates from time of transplant were 86 and 92 % for the refractory and the chemosensitive groups, respectively (P ¼ 0.53) (Figure 1a) . The 1-year PFS rate from the time of transplant was similar for the two groups (chemosensitive: 83% vs primary refractory: 70%) (Figure 1b) . Figure 1c depicts the overall survival from the time of initial anti-myeloma therapy for the two groups.
Various known risk factors were examined for their effect on PFS following transplant in those patients who had responded (n ¼ 146). Prognostic factors found to be significant for post-transplant relapse-free survival in univariate analyses are listed in Table 2 . Multivariate analyses were conducted including these variables as well as refractory vs chemosensitive disease. After accounting for all of these variables in the multivariate model for posttransplant relapse-free survival, the factors that were significant were: PCLI, cytogenetics, presence of circulating plasma cells at harvest, M-protein level, and achievement of CR with transplant (Table 3) .
Discussion
In the early 1980s, McElwain and Powles demonstrated that high doses of Melphalan can overcome drug resistance in myeloma cells and provided the proof of principle for high-dose therapy. 20 Later it was shown that the toxicity associated with this approach could be ameliorated by infusion of autologous bone marrow. 21 Subsequent clinical trials demonstrated a survival advantage for myeloma patients receiving high-dose therapy and stem cell rescue compared to conventional chemotherapy, and it has since become the standard of care for those who can undergo the procedure. 7, 8, 22, 23 The conventional approach to high-dose therapy in myeloma has involved initial tumor reduction with conventional chemotherapy followed by peripheral blood stem cell collection and then reinfusion following a melphalan-containing conditioning regimen. The recognition that alkylating agents prior to stem cell collection impaired the mobilization yields led to the use of various non-alkylating agent regimens for initial therapy of myeloma. 24 However, the effect of clinical response to induction therapy on long-term outcome after HDT in myeloma is still not fully understood. 25 Results extrapolated from the experience in other diseases like lymphoma would argue against offering high-dose therapy to patients failing initial therapy. 11, 12 In this study, we reviewed our experience with HDT for patients who failed to respond to a non-alkylator containing induction therapy and then received transplant.
This study evaluated the results of this approach in a group of uniformly treated patients undergoing transplantation at a single institution. Nearly a third of the patients among our group of patients had refractory disease. This is higher than reported in studies that used induction therapy to maximal response, 26 however, this is comparable to studies using similar induction therapies. 27 Some of these patients may have obtained a response or improved their response following cyclophosphamide pulsing used as part of mobilization procedure. However, we did not routinely assess disease status between mobilization and transplant. The differences between the groups in terms of their baseline features at transplant were primarily related to the more active disease in those not responding to induction therapy. The characteristics of this patient group are comparable to that in most studies of HDT in myeloma. The induction therapy in these patients included regimens commonly used as initial therapy for myeloma. The proportion of patients with cytogenetic abnormalities was higher in the refractory group, a finding previously reported. 13 It is conceivable that these genetic changes may have contributed to the primary resistance to therapy seen in this group.
The transplant-related toxicities observed in this study were similar to those seen in other studies using similar conditioning regimens. This is important since some of the patients with primary refractory disease are likely to have a poorer performance status compared to those in whom disease has responded to initial therapy. There was no difference between the two groups in terms of the engraftment kinetics. Incidence of post-transplant bacteremic episodes appears to be similar between the groups as well.
We observed an overall response rate of 92% in the primary refractory group following HDT. Though less than that observed in the responsive group, this is an excellent result considering the fact that these patients had disease unresponsive to initial therapy. This response rate is similar to those observed in some of the studies and is higher than in some others. 14, [28] [29] [30] [31] [32] [33] [34] We also observed a 20% CR rate in refractory patients, slightly lower compared to those with chemosensitive disease. Though HDT therapy in myeloma is usually associated with a high response rate, most of the patients will eventually relapse. One would speculate that there would be a higher relapse risk in patients with refractory disease. These patients have higher number of bone marrow plasma cells at the time of the transplant, which has been shown to predict for shorter relapse-free survival. 35 Also, the primary refractory group patients had a higher proportion of patients with circulating plasma cells at the time of harvest, another important prognostic factor for relapse. 36 In this group of patients, the median and the 1-year estimates of relapse-free and overall survival does not appear to be significantly different between the two groups. However, longer follow-up may unmask the possible differences in survival between the two groups, as well as demonstrate the impact of response, if any. Our results here warrant further investigation with a larger cohort of patients that will provide the ample power for all comparisons of interest. Multivariate analysis in this small group of patients demonstrated the importance of cytogenetics, complete response to transplant, and labeling index (Table 3) for PFS post transplant. However, the absence of other known prognostic factors like beta2 microglobulin from this model may be related to the small number of patients.
Previous studies have also suggested that refractory patients benefit from high-dose therapy. Investigators at MD Anderson cancer center studied the role of HDT for primary resistant myeloma (resistant to VAD or other high-dose dexamethasone regimens).
14,29 They noted significant tumor reduction and an improvement in overall survival among 41 patients with resistant disease compared to a control group who did not undergo HDT. The advantage was limited to those patients undergoing HDT within a year of their initial diagnosis. In a recent update of their experience, they reported on the results of HDT in 113 patients who failed to achieve a 75% reduction in the tumor mass with initial therapy, comparing them to a control group continuing on standard therapy for non-medical (financial) reasons. There was an 88% response rate with HDT, including a 17% complete response rate. The median survival from the initial therapy was 4 years in the HDT group compared to 2.8 years in the control group. 28 Those attaining a CR had the best overall survival. 37 Investigators from the Royal Marsden reviewed their experience with HDT in primary resistant myeloma and concluded that these patients derive definite benefit with this approach. 26 They compared 43 patients who had failed to respond to an induction therapy consisting of cyclophosphamide, vincristine, doxorubicin, and methylprednisolone (C-VAMP) to 179 patients who had at least a partial response. In this study, patients received induction therapy to maximum response. After HDT with Melphalan 200 mg/ m 2 conditioning, 40% of the refractory patients obtained a CR. The event-free and overall survival at 5 years for the refractory patients achieving a CR was similar to those who had a response to initial induction therapy. The response to HDT appeared to be independent of the initial response. By confirming the results in a different group of patients from [30] [31] [32] [33] [34] Firm conclusions are difficult to draw from these nonuniformly treated groups of patients, but most have suggested a benefit with HDT. In a review of the French registry experience, no difference was found in terms of the remission duration following high-dose therapy between those responding and not responding to induction therapy. 38 In a recent clinical trial evaluating the efficacy and safety of a conditioning regimen containing thiotepa, busulfan, and cyclophosphamide, the median survival of 35 months among patients with primary refractory disease was comparable to the 48 months for those with chemosensitive disease (P ¼ NS). 39 In addition, when compared to those patients in resistant relapse, those with primary resistance achieve significantly higher response rates with HDT. In a study of tandem transplants, patients with primary refractory disease had improved event-free (23 vs 14 m) and overall survival (39 vs 25 m) compared to those in resistant relapse. 40 The survival for the primary refractory patients appeared comparable to the results obtained in patients with responsive disease.
Our result reinforces the benefit of offering up-front transplantation in refractory patients. High-dose melphalan is capable of overcoming resistance to steroid-based therapies. It is likely that resistance to these therapies is mediated by mechanisms completely different from that of alkylator resistance. Also, the relatively short duration of therapy (median 6 months from diagnosis to transplant in this study) allows less opportunity for development of resistant clones.
Based on this and other reports, 26 we would recommend offering high-dose therapy to patients with primary refractory disease. They can expect higher response rates than those seen with conventional salvage chemotherapy regimens with outcomes for responding patients similar to those with chemosensitive disease. Longer follow-up is required to determine if the responses among patients with primary resistant disease are as durable as those obtained in patients with chemosensitive disease. Further studies including larger number of patients with longer follow up is required to confirm these results.
